May 8, 2025 04:39PM
May 8, 2025 04:05PM
Mar 14, 2025 06:52AM
Mar 13, 2025 04:05PM
Nov 7, 2024 05:13PM
Nov 7, 2024 04:05PM
Aug 8, 2024 05:03PM Regulus Therapeutics (RGLS) Misses Q2 EPS by 5c
Aug 8, 2024 04:05PM
May 9, 2024 04:44PM
May 9, 2024 04:05PM
Mar 21, 2024 04:05PM
Nov 9, 2023 04:37PM
Nov 9, 2023 04:05PM
Aug 8, 2023 05:35PM Regulus Therapeutics (RGLS) Tops Q2 EPS by 4c
Aug 8, 2023 04:05PM
Jul 18, 2023 08:00AM
Jun 20, 2023 08:00AM
Jun 12, 2023 08:04AM
Jun 12, 2023 08:00AM
May 16, 2023 08:02AM
May 16, 2023 08:00AM Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 11, 2023 04:50PM
May 11, 2023 04:05PM
Apr 12, 2023 04:09PM
Apr 12, 2023 04:05PM
Mar 23, 2023 04:05PM
Feb 9, 2023 08:00AM
Dec 12, 2022 08:01AM Regulus Therapeutics (RGLS) announces Simos Simeonidis resigns from board
Dec 12, 2022 08:00AM
Nov 29, 2022 08:00AM
Nov 10, 2022 04:23PM
Nov 10, 2022 04:05PM
Nov 3, 2022 08:00AM
Nov 2, 2022 08:00AM
Oct 27, 2022 04:05PM Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
Sep 12, 2022 08:15AM
Sep 12, 2022 08:00AM
Sep 2, 2022 04:05PM
Aug 11, 2022 04:10PM
Aug 4, 2022 08:00AM
Jun 21, 2022 08:01AM
Jun 21, 2022 08:00AM Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jun 13, 2022 08:00AM
May 17, 2022 04:30PM
May 12, 2022 04:05PM
May 11, 2022 08:01AM
May 11, 2022 08:00AM
May 5, 2022 04:05PM
Mar 24, 2022 08:00AM Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital
Mar 10, 2022 04:26PM

1,198,585 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All